Does Dr. GHASSAN EL-HADDAD have financial conflicts of interest?

Dr. GHASSAN EL-HADDAD (M.D.) has received a total of $60,411 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $52,897 in personal promotional payouts (consulting, meals, travel) and $7,515 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. GHASSAN EL-HADDAD?

According to CMS Open Payments data, Dr. GHASSAN EL-HADDAD received funding from NOVARTIS PHARMACEUTICALS CORPORATION ($12,807), BAYER HEALTHCARE PHARMACEUTICALS ($8,477), and TERUMO MEDICAL CORPORATION ($7,630).

Does Dr. GHASSAN EL-HADDAD receive research grants or speaking fees?

Dr. GHASSAN EL-HADDAD has received $52,897 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $7,515 in clinical research grants.

DR. GHASSAN EL-HADDAD

M.D.Real-Time Hydrated

Specialty: Radiology, Vascular & Interventional Radiology

Practice Location: TAMPA, FL 33612

NPI Number: 1295808939

LIFETIME INDUSTRY VALUE

$60,411

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. EL-HADDAD is a verified Radiology, Vascular & Interventional Radiology practitioner based in TAMPA, FL.

Between 2021 and 2025, Dr. EL-HADDAD had an overall industry promotional and research financial footprint of $60,411 as recorded in the federal CMS Open Payments database.

$52,897 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$7,515 was allocated to sponsored clinical trials and medical research activities.

Dr. EL-HADDAD's primary funding source is NOVARTIS PHARMACEUTICALS CORPORATION, which accounts for $12,807 (representing 21.2% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 1

$12,807

21.2%

BAYER HEALTHCARE PHARMACEUTICALS

Rank 2

$8,477

14%

TERUMO MEDICAL CORPORATION

Rank 3

$7,630

12.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.